A New Concern for Transfeminine Health: The Alzheimer’s Link
A recent cohort study published in Alzheimer’s & Dementia investigates the prevalence of Alzheimer’s disease and related dementias (ADRD) among older transfeminine adults. Analyzing electronic health records of 856 transfeminine individuals aged 65 and over, researchers compared their ADRD rates to matched cisgender men and women. The findings indicate a trend toward higher ADRD prevalence in the transfeminine group, with adjusted odds ratios of 1.39 compared to cisgender men and 1.29 compared to cisgender women. Notably, the association was stronger for transfeminine adults with a documented history of gender-affirming hormone therapy (GAHT), where the odds ratios increased to 1.75 and 1.70, respectively. This research highlights a potential disparity in neurocognitive disorder risk within a specific demographic, suggesting a need for targeted clinical awareness and management strategies in psychiatric and geriatric care.
Study Significance: For clinicians in psychiatry and mental health, this study underscores the importance of integrating dementia risk assessment into the holistic care of older transgender patients, particularly those on GAHT. It points to a critical intersection between gender-affirming care, neuropsychiatry, and geriatric mental health, suggesting that screening for cognitive decline and early intervention for neurocognitive disorders should be prioritized in this population. This finding necessitates a more nuanced understanding of how long-term hormone therapy and minority stress may interact to influence brain health and dementia trajectories.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
